---
document_datetime: 2024-04-10 12:07:18
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/myfenax-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: myfenax-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.1616621
conversion_datetime: 2025-12-25 12:07:17.083907
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Myfenax

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0052/G            | This was an application for a group of variations. | 04/04/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |             |                                                                                                                                                                                                                         |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10550 /202305 | Periodic Safety Update EU Single assessment - mycophenolate mofetil, mycophenolic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/01/2024 | 25/03/2024 | SmPC        | Please refer to CellCept, Myclausen, Mycophenolate mofetil Teva, Myfenax EMEA/H/C/PSUSA/00010550/202305 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| N/0051              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/09/2023 | 25/03/2024 | PL          |                                                                                                                                                                                                                         |
| IB/0048/G           | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a | 23/06/2022 | 26/06/2023 | SmPC and PL |                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                     | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                   |            |            |      |                                                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1508             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                             | 23/05/2022 | n/a        |      |                                                                                                                                            |
| PSUSA/10550 /202105 | Periodic Safety Update EU Single assessment - mycophenolate mofetil, mycophenolic acid                                                                                                                                                                       | 16/12/2021 | 17/02/2022 | PL   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10550/202105. |
| IB/0047             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 08/10/2021 | 17/02/2022 | SmPC |                                                                                                                                            |
| N/0046              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 17/09/2021 | 17/02/2022 | PL   |                                                                                                                                            |
| IA/0044             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                  | 13/04/2021 | n/a        |      |                                                                                                                                            |
| PSUSA/10550 /202005 | Periodic Safety Update EU Single assessment - mycophenolate mofetil, mycophenolic acid                                                                                                                                                                       | 10/12/2020 | 19/02/2021 | SmPC | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for                     |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                        | PSUSA/10550/202005.   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------|
| IA/0043     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                            | 01/02/2021 | 17/02/2022 | Annex II and PL        |                       |
| IA/0041     | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                              | 17/06/2020 | n/a        |                        |                       |
| IAIN/0040/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 12/06/2020 | 18/11/2020 | SmPC, Labelling and PL |                       |
| IB/0039     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                             | 16/03/2020 | 18/11/2020 | SmPC, Annex II and PL  |                       |
| IAIN/0038/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g.                                                                                                                                                                                                                                                                                                      | 11/12/2019 | 18/11/2020 | SmPC, Labelling and PL |                       |

<div style=\"page-break-after: always\"></div>

|                     | tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes   |            |            |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0035             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                           | 04/12/2019 | n/a        |                        |                                   |
| PSUSA/10550 /201905 | Periodic Safety Update EU Single assessment - mycophenolate mofetil, mycophenolic acid                                                                                                                                                                                                                 | 28/11/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0036             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                             | 22/10/2019 | n/a        |                        |                                   |
| IA/0037             | B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure                                                                                                                                                                | 27/09/2019 | n/a        |                        |                                   |
| PSUSA/10550 /201805 | Periodic Safety Update EU Single assessment - mycophenolate mofetil, mycophenolic acid                                                                                                                                                                                                                 | 29/11/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0033/G           | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following                                                                                                                                                      | 14/09/2018 | 04/10/2019 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                  |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0031             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                  | 22/06/2018 | n/a        |                  |                                                                                                                                            |
| N/0030              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                             | 19/03/2018 | 04/10/2019 | Labelling and PL |                                                                                                                                            |
| PSUSA/10550 /201705 | Periodic Safety Update EU Single assessment - mycophenolate mofetil, mycophenolic acid                                                                                                                                                                                                                                                                                                                                       | 14/12/2017 | 05/03/2018 | SmPC and PL      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10550/201705. |
| IA/0028             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                  | 22/05/2017 | n/a        |                  |                                                                                                                                            |
| IA/0027             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                | 13/04/2016 | 12/04/2017 | Annex II and PL  |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IB/0026   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 28/01/2016   | 18/02/2016   | SmPC, Annex II and PL   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|
| IAIN/0025 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 02/12/2015   | n/a          |                         |
| IB/0024/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 10/08/2015   | 18/02/2016   | SmPC and PL             |

<div style=\"page-break-after: always\"></div>

|           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                                  |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| IB/0023   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 22/04/2015 | 18/02/2016 | SmPC and PL                      |
| T/0022    | Transfer of Marketing Authorisation                                                                                                                                                                                                                            | 09/01/2015 | 27/01/2015 | SmPC, Labelling and PL           |
| IB/0021   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                      | 13/10/2014 | 30/10/2014 | SmPC, Labelling and PL           |
| IB/0020   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 30/10/2013 | 30/10/2014 | SmPC, Annex II, Labelling and PL |
| IAIN/0019 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                 | 24/05/2013 | n/a        |                                  |

<div style=\"page-break-after: always\"></div>

| IA/0018     | B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                  | 01/02/2013   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0017     | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                          | 21/11/2012   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0015      | Renewal of the marketing authorisation.                                                                                                                                                                                                          | 20/09/2012   | 19/11/2012 | SmPC, Annex II, Labelling and PL | Based on the review of the available information, the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers the benefit/risk profile of Myfenax continues to be favourable. The CHMP is also of the opinion that the renewal can be granted with unlimited validity. |
| IB/0016     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH   | 13/09/2012   | 19/11/2012 | SmPC and PL                      | Update of Section 4.5 of the SmPC to include information regarding the interaction with proton pump inhibitors following the outcome of PSUR 18 assessment (covering period: 01.05.08-30.04.11) of the Reference Product. The Package Leaflet has been updated accordingly.                                                                                                                    |
| IAIN/0014/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing | 16/03/2012   | 11/06/2012 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IA/0013   | B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                          | 15/09/2011   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0012   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                           | 10/02/2011   | n/a        | SmPC, Annex II and PL  | Changes to the PIL section 2 (Pregnancy and breast- feeding) recommended by the CHMP following the assessment of the originator product. The MAH also took the opportunity to: - Delete the version number of the DDPS from Annex IIB of the Marketing Authorisation. - Change the name of the active ingredient from \"mycophenolate\" to \"mycophenolate mofetil\" throughout the SmPC and PIL. - Make minor linguistic changes to comply with QRD |
| N/0010    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                         | 12/11/2010   | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0011/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 21/10/2010   | 21/10/2010 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| N/0008   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13/07/2010   | n/a        | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007  | Update of section 4.8 of the SPC to include information on isolated reports of interstitial lung disease and pulmonary fibrosis. This change was made to bring Myfenax's product information in line with the reference medicinal product CellCept. Update of Summary of Product Characteristics                                                                                                                                                                                                                                                                                                                                    | 21/01/2010   | 23/03/2010 | SmPC        | In September 2009, a variation (EMEA/H/C/82/II/93) to the marketing authorisation for CellCept was approved to update section 4.8 of the SPC to include information on isolated reports of ILD and pulmonary fibrosis. In November 2009, the Marketing Authorisation Holder for Myfenax submitted a Type II variation to bring the product information for Myfenax in line with CellCept's product information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0004  | Update of section 4.4 and 4.8 of the SPC to include information on pure red cell aplasia. Update of sections 4.8 of the SPC to include information on acquired Pelger-Huet anomaly and to include the term \"gingival hyperplasia\". Update of section 4.5 of the SPC to include possible drug-drug interaction of Myfenax in combination with ciprofloxacin or amoxicillin plus clavulanic acid. The Package Leaflet was updated accordingly. These changes were made to bring Myfenax's product information in line with its reference medicinal product CellCept. Update of Summary of Product Characteristics and Package Leaflet | 23/07/2009   | 21/08/2009 | SmPC and PL | In April 2009, a variation (EMEA/H/C/82/II/86) to the marketing authorisation for CellCept was approved to update sections 4.4 and 4.8 of the SPC to include information on pure red cell aplasia; to update section 4.8 of the SPC to include information on acquired Pelger-Huet anomaly and to include the term \"gingival hyperplasia\"; to update of section 4.5 of the SPC to include possible drug- drug interaction of Myfenax in combination with ciprofloxacin or amoxicillin plus clavulanic acid. The Package Leaflet was updated accordingly. On 27 April 2009, the Marketing Authorisation Holder (MAH) for Myfenax was requested the submission of a Type II variation, within two months, to match the changes introduced by CellCept variation II/0086. In June 2009, the MAH submitted the requested Type II variation to bring the product information for Myfenax in line with CellCept's product information. |
| IB/0006  | IB_17_a_Change in re-test period of the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15/07/2009   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IA/0005   | IA_15_a_Submission of Ph. Eur. certificate for active substance - approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                             | 01/07/2009   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0003   | Inclusion (following adoption by the CHMP of a safety variation to the Marketing Authorisation of the Innovator product, CellCept) of a new warning in sections 4.4 and 4.8 of the Myfenax's (mycophenolate mofetil) summary of product characteristics (SPC) related to cases of BK virus- associated nephropathy, as well as cases of JC virus- associated progressive multifocal leukoencephalopathy (PML) reported in patients treated with mycophenolate mofetil. Update of Summary of Product Characteristics | 22/01/2009   | 26/02/2009 | SmPC                   | In October 2008, a variation (EMEA/H/C/82/II/84) to the marketing authorisation for CellCept was approved to update sections 4.4 and 4.8 of the SPC to implement the warning on BK virus associated nephropathy (BKVN) and JC virus associated progressive multifocal leukoencephalopathy (PML) requested by the CHMP in July 2008. In 08 October 2008, the Marketing Authorisation Holder (MAH) for Myfenax was requested the submission of a Type II variation, within two months, to match the changes introduced by CellCept variations II/0084. In November 2008, the MAH submitted the requested Type II variation to bring the SPC for Myfenax in line with CellCept's product |
| IB/0002   | IB_34_b_01_Change in colour/flavour - Increase or addition: colouring system                                                                                                                                                                                                                                                                                                                                                                                                                                        | 02/12/2008   | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0001   | Update of sections 4.4 and 4.8 of the Summary of product Characteristics (SPC) to include information that cases of Progressive Multifocal Leukoencephalopathy (PML), sometime fatal, have been reported in Myfenax treated patients. Section 4.6 of the SPC was also updated to include that cases of spontaneous abortion have been reported in patients exposed to Myfenax. The Package Leaflet was updated accordingly. These changes were made                                                                 | 26/06/2008   | 25/07/2008 | SmPC and PL            | The reference medicinal product for Myfenax is CellCept (which was first granted marketing authorisation in the EU on 14 February 1996 for the prevention of renal transplant rejection when used in combination with ciclosporin and corticosteroids, and subsequently for prevention of cardiac and hepatic transplant rejection). On 28 February 2008, two variations (EMEA/H/C/000082/II/0082 and                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| to bring the Myfenax's product information in line with CellCept (reference medicinal product for Myfenax). In addition, the MAH corrected the contact details for Hungary and France in the \"Marketing Authorisation Holder and Manufacturer\" section of the Package Leaflet. Update of Summary of Product Characteristics and Package Leaflet   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|